153 related articles for article (PubMed ID: 33532001)
1. Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma.
Mao J; Yang X; Lin J; Yang X; Wang D; Zhang L; Bai Y; Bian J; Long J; Xie F; Huang H; Sang X; Chen S; Zhao H
J Cancer; 2021; 12(5):1555-1562. PubMed ID: 33532001
[No Abstract] [Full Text] [Related]
2. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
Zhang G; Gong S; Pang L; Hou L; He W
Front Oncol; 2021; 11():659217. PubMed ID: 34012920
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study.
Geng Q; Shen H; Zhu W; Lu Y; Wang M; Jiang H; Li D
Onco Targets Ther; 2020; 13():11529-11535. PubMed ID: 33204107
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma.
Lin G; Wang B; Wu X; Sun T; Chen L; Lu C; Wang N
Cancer Manag Res; 2020; 12():11523-11526. PubMed ID: 33204163
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
Wu F; Zhang S; Xiong A; Gao G; Li W; Cai W; Su C; Chen X; Zhou F; Zhao J; Ren S; Zhou C
Clin Lung Cancer; 2018 Nov; 19(6):e831-e842. PubMed ID: 30026059
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients.
Zhang L; Chen L; Yu H
Invest New Drugs; 2020 Aug; 38(4):1186-1191. PubMed ID: 31637668
[TBL] [Abstract][Full Text] [Related]
7. An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma.
Li L; Xiao S; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Zhang X; Chang Y; Nan F; Yan J; Li Z; Shi M; Young KH; Zhang M
Oncotarget; 2018 Mar; 9(22):16213-16219. PubMed ID: 29662638
[TBL] [Abstract][Full Text] [Related]
8. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).
Chu L; Chen Y; Liu Q; Liang F; Wang S; Liu Q; Yu H; Wu X; Zhang J; Deng J; Ai D; Zhu Z; Nie Y; Zhao K
Oncologist; 2021 Jun; 26(6):e925-e935. PubMed ID: 33393167
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
[TBL] [Abstract][Full Text] [Related]
11. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.
Hou Z; Zhu K; Yang X; Chen P; Zhang W; Cui Y; Zhu X; Song T; Li Q; Li H; Zhang T
Ann Transl Med; 2020 Sep; 8(17):1047. PubMed ID: 33145266
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study.
Nie C; Lv H; Xing Y; Chen B; Xu W; Wang J; Chen X
BMC Cancer; 2021 Feb; 21(1):189. PubMed ID: 33622272
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study.
Hu Y; Lin H; Hao M; Zhou Y; Chen Q; Chen Z
Cancer Manag Res; 2020; 12():5345-5351. PubMed ID: 32753952
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
15. Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer.
Zhang Z; Zhang Y; Luo F; Ma Y; Fang W; Zhan J; Li S; Yang Y; Zhao Y; Hong S; Zhou T; Zhang Y; Zhao S; Huang Y; Zhao H; Zhang L
Clin Transl Med; 2020 Jun; 10(2):e33. PubMed ID: 32508029
[TBL] [Abstract][Full Text] [Related]
16. Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.
Song Z; Lou G; Wang Y; Yang Z; Wang W; Ji Y; Chen S; Xu C; Hu X; Zhang Y
BMC Med; 2022 May; 20(1):154. PubMed ID: 35534877
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
Wang D; Yang X; Long J; Lin J; Mao J; Xie F; Wang Y; Wang Y; Xun Z; Bai Y; Yang X; Guan M; Pan J; Seery S; Sang X; Zhao H
Front Oncol; 2021; 11():646979. PubMed ID: 33912461
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study.
Sun F; Lu S; Zhen Z; Zhu J; Wang J; Huang J; Zhang Y; Li H; Cai R; Liu M; Wu L; Sun X; Zhang Y
Cancer Manag Res; 2020; 12():6177-6185. PubMed ID: 32801866
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.
Xu J; Liu X; Yang S; Zhang X; Shi Y
Asia Pac J Clin Oncol; 2018 Jun; 14(3):264-269. PubMed ID: 29243413
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma.
Hu Y; Hao M; Chen Q; Chen Z; Lin H
Am J Transl Res; 2020; 12(10):6584-6598. PubMed ID: 33194055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
